Monoclonal gammopathy of undetermined significance classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D. [2]
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance classification On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance classification |
|
FDA on Monoclonal gammopathy of undetermined significance classification |
|
on Monoclonal gammopathy of undetermined significance classification |
|
Monoclonal gammopathy of undetermined significance classification in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance classification |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Overview[edit | edit source]
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:[1]
Classification[edit | edit source]
Monoclonal gammopathy of undetermined significance (MGUS) may be classified according to cytogenetic differences into the following subtypes/groups:[1]
| Abnormalities in cytogenes | Affected genes |
| IgH translocation: | |
| t(11;14), q(13;32) | cyclin D1 |
| t(4;14)(p16;q32) | FGFR-3, and MMSET |
| t(14;16)(q32;q23) | C-MAF |
| t(6;14)(q32;q11) | MAFB |
| IgH non-translocated : | |
| Hyper diploid | Numerous |
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
References
- ↑ 1.0 1.1 Rajkumar SV, Kyle RA, Buadi FK (October 2010). "Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence". Mayo Clin. Proc. 85 (10): 945–8. doi:10.4065/mcp.2010.0520. PMC 2947967. PMID 20884827.